Sanofi invests $700 million in genetic medicines
Sanofi’s subsidiary Genzyme has expanded its partnership with Alnylam Pharmaceuticals to develop drugs for rare genetic diseases.
The $700 million investment will give Genzyme/Sanofi a 12 per cent share of Alnylam, and access to its drug candidates – for example, its phase 2 familial amyloid cardiomyopathy treatment.
Sanofi pays $700 million for Alnylam drugs and stake (Bloomberg).
Genzyme and Alnylam expand collaboration on rare genetic diseases (Sanofi press release).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.